The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Optometry
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Campaigns & Insights
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2026 / November / Kiora Licenses Late-Stage CRAO Treatment
Retina Latest News

Kiora Licenses Late-Stage CRAO Treatment

Company plans multinational Phase 3 trial of oral neuroprotective therapy

11/20/2026 2 min read

Share

  • Full Article
  • Summary
  • Listen
  • Scorecard
  • Quiz
Objective:

The article examines the objective, findings, and clinical context described in Kiora Licenses Late-Stage CRAO Treatment.

Approach:
  • License: Kiora obtained exclusive development and commercialization rights to KIO-401 outside Asia from Senju Pharmaceutical.
  • Mechanism: KIO-401 (mitucapistat) is an investigational oral inhibitor of activated calpain, a protease implicated in ischemia-related cellular injury.
  • Planned studies: Kiora plans a multinational Phase 3 registration trial for acute CRAO, targeted to begin in 2027. Trial initiation depends on financing and regulatory alignment; the final design will follow regulatory discussions.
Key Findings:
  • In a randomized Japanese Phase 2a study, KIO-401 showed statistically significant visual-acuity improvement compared with a prospective observational registry.
  • A randomized, double-masked Phase 3 trial reported improved best-corrected visual acuity, including statistically significant benefits among participants classified as legally blind at baseline under WHO criteria.
  • Kiora plans to study KIO-401 in a Phase 2b NAION trial in 2028; the company is also exploring possible glaucoma applications, which would require further investigation.
Interpretation:

Duke University’s Brian Mac Grory described the reported results as the first encouraging results for a neuroprotective drug for CRAO and said they support further evaluation of KIO-401.

Limitations:
  • The planned multinational Phase 3 trial has not yet begun; its final design remains subject to regulatory discussions.
  • Trial initiation is dependent on financing and regulatory alignment.
  • The context does not provide trial sample sizes, effect estimates, or detailed safety results.
Conclusion:

Under the agreement, Kiora will pay Senju $3.5 million upfront, with additional development and commercialization milestone payments and royalties.

Sources:
  • Kiora Pharmaceuticals (source provided in article context)

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Your Privacy Choices
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: